GlassScriptPhysician profile
Omar Wazzan
NPI 1093255952
$1,260.78
in general payments reported to CMS, 2019-2025
20 companies · $355 in 2025
The $355 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $27.26 · 2021: $88.01 · 2022: $438 · 2023: $187 · 2024: $165 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $707.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $385.71 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $169.78 | 2021-2024 | Ajovy |
| Ucb, INC. | $121.60 | 2021-2024 | Briviact |
| Livanova USA, INC. | $106.24 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Biohaven Pharmaceutical Holding Company LTD. | $71.18 | 2022 | |
| Lilly USA, LLC | $52.22 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $42.77 | 2021 | |
| Jazz Pharmaceuticals INC. | $38.01 | 2025 | |
| Pfizer INC. | $32.47 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $27.59 | 2023 | Nuedexta |
| Genzyme Corporation | $27.26 | 2020 | |
| Biogen, INC. | $27.26 | 2023 | Vumerity |
| Janssen Biotech, INC. | $25.71 | 2025 | |
| Eisai INC. | $24.92 | 2023 | |
| Argenx US, INC. | $23.07 | 2023 | Vyvgart |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $22.12 | 2022 | |
| Microtransponder, INC. | $22.01 | 2025 | |
| Horizon Therapeutics Plc | $19.75 | 2022 | |
| Amgen INC. | $14.84 | 2022 | |
| Aucta Pharmaceuticals, INC. | $6.27 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Wazzan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.